Zimmer Biomet Acquires Monogram Technologies for $144M in Cash and Earnout

Zimmer Biomet Holdings has agreed to acquire Monogram Technologies for $144 million, with a cash consideration of $4.04 per share and an earnout of $441.46 million. The deal is expected to be neutral to adjusted earnings per share in 2025-2027 and accretive thereafter, with revenue growth beginning in 2027. The transaction is subject to regulatory approval and shareholder approval, with an expected completion in the second half of 2025.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered into a definitive agreement to acquire Monogram Technologies Inc. (NasdaqCM: MGRM) for $144 million. The deal, which includes a cash consideration of $4.04 per share and an earnout of $441.46 million, is expected to be neutral to adjusted earnings per share in 2025-2027 and accretive thereafter. Revenue growth is anticipated to begin in 2027.

The acquisition will enhance Zimmer Biomet's ROSA Robotics platform by integrating Monogram's advanced robotic solutions, including both semi- and fully autonomous systems. Monogram's CT-based, semi-autonomous, AI-driven total knee arthroplasty robotic system received FDA 510(k) clearance in March 2025 and is expected to launch commercially in early 2027, utilizing Zimmer Biomet implants.

The transaction is subject to regulatory approval and shareholder approval and is expected to close in the second half of 2025. The deal is projected to generate high-single digit return on invested capital (ROIC) by year five, with an increasing contribution thereafter.

References:
[1] https://www.marketscreener.com/quote/stock/MONOGRAM-TECHNOLOGIES-INC-154724725/news/Zimmer-Biomet-Holdings-Inc-agreed-to-acquire-Monogram-Technologies-Inc-for-144-million-50504261/
[2] https://www.nasdaq.com/articles/zimmer-biomet-acquire-monogram-technologies-all-cash-deal-valued-about-168-mln
[3] https://ih.advfn.com/market-news/article/12606/monogram-technologies-shares-surge-after-zimmer-biomet-announces-acquisition